



July 29, 2025

The Manager
BSE Limited
Corporate Relationship Department
P. J. Towers, Dalal Street,
Mumbai – 400 001.

The Manager
The National Stock Exchange of India Limited Exchan
Plaza,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051.

BSE Scrip Code No. 524280

NSE Symbol: KOPRAN

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on July 29, 2025

Pursuant to Regulation 33 read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, the meeting of the Board of Directors held today viz., July 29, 2025 and the Board has, inter-alia, considered and approved the following:

1. Approval of Unaudited Financial Results

Unaudited Financial Results (Standalone and Consolidated) for the first quarter ended on June 30, 2025 along with Limited Review Reports of the Statutory Auditor of the Company is attached herewith. The said financial results were duly reviewed and recommended by the audit committee and approved by the Board of Directors of the Company at their respective meetings held today.

2. Appointment / Reappointment of Director

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, has approved appointment of Mr. Chandresh Gunvant Gandhi (DIN: 00707947) as Additional Director (Non-Executive Director, Independent) of the Company for a term of five years commencing from July 29, 2025 to July 28, 2030, subject to the approval of Members of the Company.

Based on the recommendation of Nomination and Remuneration Committee, Mr. Surendra Somani (DIN: 00600860) who has attained the age of 70 years, currently holding the position as Executive Vice-chairman of the Company, has been appointed as Chairman & Managing Director of the Company for a term of three years commencing from January 01, 2026 to December 31, 2028, subject to the approval of Members of the Company.

Brief details of Director is enclosed herewith as **Annexure A**



KOPRAN LTD.: Parijat House, 1076, Dr. E. Moses Road, Worli, Mumbai - 400 018. P. B. No. 9917, Tel.: (022) 4366 1111
Fax: (022) 2495 0363 Website: www.kopran.com CIN – L 24230 MH 1958 PLC 011078. E-mail: cs@kopran.com
Works: • Village Savroli, Taluka: Khalapur, District: Raigad - 410 202. Tel.: (02192) 274500 / 335 / 337 • Fax: (02192) 274025



3. Appointment of Secretarial Auditor

Pursuant to the provisions of Regulation 24A and 30 read with Schedule III of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), as amended from time to time, and based on the recommendation of the Audit Committee, M/s Smita Prabhu & Associates, Practicing Company Secretary (Unique Identification No. S2013UP222100), has been appointed as a Secretarial Auditor of the Company, to conduct secretarial audit of the Company for a period of five consecutive years from financial year 2025-26 till financial year 2029-30, subject to the approval of Members of the Company. **(Annexure B)**

4. Annual General Meeting (AGM)

The 66th AGM of the Company is scheduled to be held on Thursday, September 11, 2025 at 11:30 A.M. (IST) through Video Conferencing/Other Audio-Visual Means (VC/OAVMs).

5. Resignation of Mr. Susheel Somani (DIN: 00601727), Non-Executive Director of the Company

Mr. Susheel Somani (DIN: 00601727), Chairman of the Board/Non-Executive Director of the Company has resigned from his office with effect from closure of business hours on July 29, 2025. **(Annexure C)**. The Board of Directors and Management of the Company express sincere appreciation and gratitude for his significant contribution during his tenure as Chairman and Director of the Company.

Kindly publish the outcome on your websites.

The Board Meeting commenced at HH:MM 12.30 & concluded at HH:MM 14:05

Regards,

For Kopran Limited

Sunil Sodhani
Company Secretary & Compliance Officer
Membership No. FCS 3897

Encl : As above



Annexure A

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular No. SEBI/HO/CFD/CFD- PoD-1/P/CIR/ 2023/123 dated July 13, 2023

| Sr. No. | Particulars | Mr. Chandresh Gunvant Gandhi (DIN: 00707947) |
|---------|---|---|
| 1. | Reason for change viz. appointment, resignation, removal, death or otherwise; | Appointment of Additional Director (Non-Executive, Independent) |
| 2. | Date of appointment/cessation (as applicable) & term of appointment; | Appointment for the first term of 5 consecutive years, i.e, from July 29, 2025 to July 28, 2030 (both days inclusive), subject to approval of the shareholders at Annual General Meeting of the Company. |
| 3. | Brief profile (in case of appointment) | <p>Mr. Chandresh Gunvant Gandhi has been in professional practice as Chartered Accountant for more than 30 years. He is also a Managing Partner of M/s Dosi and Jain, Chartered Accountant Firm (Brief details of assignment undertaken by the firm)</p> <ul style="list-style-type: none"> ● Concurrent Auditor of a leading foreign bank for more than two decades for their All India Inward and Outward remittances-FTU unit and Imports/Exports Trade Unit as per Guidelines of the Reserve Bank of India. ● Internal Auditor for the leading commodity exchange in India for almost 10 years ● Statutory auditor of a listed company for more than 20 years. ● Conducted Statutory audit of nationalised bank branches allotted on the basis of Empanelment ● Provided advisory services as well as representation before the authorities in the field of Auditing and Accounting, Local and International Taxation including Interpretation of Tax Treaties, Transfer Pricing and FEMA issues relating to Inbound |

| | | |
|----|--|---|
| | | and Outbound Investments under the RBI guidelines for NRIs, local corporates and foreign companies. During his tenure, he has advised on cross border transactions involving structuring from taxation point of view under the DTAA's with various countries and reporting compliances as per the RBI Guidelines and represented before the tax authorities in assessments/appeals as well the compounding matters with the RBI. |
| 4. | Disclosure of relationships between directors (in case of appointment of a director); | None |
| 5. | Information as required pursuant to BSE circular ref no. LIST/COMP/ 14/ 2018-19 and the National Stock Exchange of India Limited with ref no. NSE/CML/2018/24, dated June 20, 2018 | Not debarred from holding the office of director pursuant to any SEBI order or any such authority. |
| 6. | Details of shareholding in the company | NIL |

| Sr. No. | Particulars | Mr. Surendra Somani (DIN: 00600860) |
|---------|--|---|
| 1. | Reason for change viz. appointment, resignation, removal, death or otherwise; | Pursuant to resignation of Mr. Susheel Somani w.e.f end of business hours on July 29, 2025, Mr. Surendra Somani is been appointed as Chairman & Managing Director of the Company. |
| 2. | Date of appointment/ cessation (as applicable) & term of appointment; | Appointment is for a period of three years with effect from January 01, 2026. His tenure as Chairman & Managing Director will expire on December 31, 2028. |

| | | |
|----|--|---|
| 3. | Brief profile (in case of appointment) | <p>Mr. Surendra Somani aged 70 years, is a Commerce Graduate from Mumbai University with around 4 decades of rich experience and knowledge of the Pharmaceutical Industry. His core strength includes Corporate Strategy, Finance, Business Development, and Regulatory Affairs. He looks after the overall management of the Company since 1981.</p> <p>Mr. Surendra Somani belongs to the promoter group.</p> |
| 4. | Disclosure of relationships between directors (in case of appointment of a Director); | Father of Mr. Varun Somani |
| 5. | Information as required pursuant to BSE circular ref no. LIST/COMP/ 14/ 2018-19 and the National Stock Exchange of India Limited with ref no. NSE/CML/2018/24, dated June 20, 2018 | Not debarred from holding the office of director pursuant to any SEBI order or any such authority. |
| 6. | Details of shareholding in the company: a) On own b) For other persons on a beneficial basis held in firm where he is a partner | 4,10,075 17,64,750 |

Annexure B

In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 SEBI Circular No. SEBI/HO/CFD/CFD-PoD2/CIR/P/2024/185 dated December 31, 2024 ('SEBI Circular'), the details are as follows:

| Sr. No. | Particulars | Description |
|---------|--|--|
| 1. | Reason for change viz., appointment of auditor | Appointment to comply with the provisions of the Section 204 of the Companies Act, 2013 and Regulation 24A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. |
| 2. | Date of appointment & term of reappointment | M/s Smita Prabhu & Associates, Practicing Company Secretaries, is appointed on July 29, 2025 as Secretarial Auditors of the Company for a period of five consecutive years from financial year 2025-26 to financial year 2029-30. |
| 3. | Brief profile (in case of appointment) | Mrs. Smita Prabhu, Proprietor of M/s. Smita Prabhu & Associates, having over 17 years of total experience. She is well-regarded for her specialized expertise in Due Diligence Audits and Secretarial Audits, and, serving a diverse range of industries including banking, financial services, IT/Telecom, pharmaceuticals, FMCG, and infrastructure, among others. |
| 4. | Disclosure of relationships between directors (in case of appointment of a director) | Not applicable |

Annexure C

| Sr. No. | Particulars | Mr. Susheel G. Somani (DIN: 000601727) |
|---------|---|--|
| 1. | Reason for change viz. appointment, resignation, removal, death or otherwise; | Resignation of Director due to his continued ill health. (copy of Resignation letter attached) |
| 2. | Date of appointment /cessation (as applicable) & term of appointment; | End of Business hours July 29, 2025 |
| 3. | Brief profile | NA |
| 4. | Disclosure of relationships between directors (in case of appointment of a director); | None |
| 5. | Information as required pursuant to BSE circular ref no. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India Limited with ref no. NSE/CML/2018/24, dated June 20, 2018 | NA |
| 6. | Details of shareholding in the company | 2,72,000 Equity shares |


KOPRAN LIMITED
STATEMENT OF CONSOLIDATED AND STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED JUNE 30, 2025

Rs. In Lakhs

| Particulars | Consolidated | | | | Standalone | | | |
|---|-----------------------|------------|------------|--------------------|-----------------------|------------|------------|--------------------|
| | For the Quarter ended | | | For the Year ended | For the Quarter ended | | | For the Year ended |
| | 30/06/2025 | 31/03/2025 | 30/06/2024 | 31/03/2025 | 30/06/2025 | 31/03/2025 | 30/06/2024 | 31/03/2025 |
| | Unaudited | Audited | Unaudited | Audited | Unaudited | Audited | Unaudited | Audited |
| (1) Revenue from Operations | 13,521.62 | 17,236.31 | 13,943.65 | 62,960.44 | 5,133.48 | 7,593.50 | 4,960.70 | 27,100.95 |
| (2) Other Income | 16.18 | 16.92 | 119.87 | 168.90 | 35.19 | 84.49 | 147.05 | 313.93 |
| (3) Foreign Exchange Gain (Net) | 239.37 | 309.18 | 142.74 | 229.30 | 144.56 | 107.25 | 64.94 | 276.50 |
| (4) Total Income (1+2+3) | 13,777.17 | 17,562.41 | 14,206.26 | 63,358.64 | 5,313.23 | 7,785.24 | 5,172.69 | 27,691.38 |
| (5) Expenses | | | | | | | | |
| (a) Cost of materials consumed | 8,030.23 | 10,919.57 | 9,151.22 | 40,099.98 | 2,736.46 | 4,387.85 | 3,183.79 | 15,363.46 |
| (b) Purchase of stock-in-trade | 38.87 | 776.71 | 48.73 | 965.81 | 38.87 | 263.18 | 122.43 | 558.78 |
| (c) Changes in Inventories of finished goods, stock-in-trade and work-in-progress | 471.28 | (160.16) | (609.93) | (604.12) | 192.17 | (275.23) | (513.16) | (184.17) |
| (d) Employee benefits expense | 1,543.29 | 1,726.18 | 1,334.76 | 6,053.62 | 734.79 | 885.61 | 635.98 | 3,001.59 |
| (e) Finance costs | 253.78 | 276.72 | 218.16 | 933.89 | 104.25 | 125.79 | 69.15 | 376.65 |
| (f) Depreciation and amortisation expense | 425.91 | 386.89 | 387.38 | 1,559.44 | 121.94 | 123.92 | 119.71 | 499.88 |
| (g) Other expenses | 2,024.90 | 2,265.33 | 2,202.57 | 9,155.16 | 923.99 | 1,103.26 | 1,003.58 | 4,495.71 |
| (h) Foreign Exchange Loss (Net) | - | - | - | - | - | - | - | - |
| Total Expenses (5) | 12,788.26 | 16,191.24 | 12,732.89 | 58,163.78 | 4,852.47 | 6,614.38 | 4,621.48 | 24,111.90 |
| (6) Profit before exceptional items and tax (4-5) | 988.91 | 1,371.17 | 1,473.37 | 5,194.86 | 460.76 | 1,170.86 | 551.21 | 3,579.48 |
| (7) Exceptional items (Net) | - | - | - | - | - | - | - | - |
| (8) Profit before tax (6-7) | 988.91 | 1,371.17 | 1,473.37 | 5,194.86 | 460.76 | 1,170.86 | 551.21 | 3,579.48 |
| (9) Tax expense | | | | | | | | |
| (a) Current Tax | 222.45 | 275.02 | 367.86 | 1,165.22 | 108.01 | 273.50 | 139.94 | 863.21 |
| (b) Deferred Tax | 21.53 | 128.42 | (4.03) | 174.45 | 0.94 | 37.43 | (13.32) | 30.65 |
| (10) Profit for the period/year (8 - 9) | 744.93 | 967.73 | 1,109.54 | 3,855.19 | 351.81 | 859.93 | 424.59 | 2,685.62 |
| (11) Other Comprehensive Income | | | | | | | | |
| (i) Items that will not be reclassified to profit and loss | | | | | | | | |
| (a) - Remeasurements of defined benefit plans | (29.03) | (132.45) | 5.45 | (116.11) | (15.59) | (70.01) | 2.55 | (62.35) |
| Income tax effect on Remeasurement of defined employee benefit plans | 7.30 | 33.33 | (1.39) | 29.23 | 3.92 | 17.62 | (0.65) | 15.70 |
| (b) - Net changes in Fair value of investments in equity shares carried at fair value through OCI | - | - | - | - | - | - | - | - |
| Income tax effect on Fair value of investments in equity shares carried at fair value through OCI | - | - | - | - | - | - | - | - |
| ii) a) Items that will be reclassified to profit or loss | | | | | | | | |
| Exchange difference in translating the financial statements of foreign operation | (1.52) | (0.60) | 0.54 | 7.39 | - | - | - | - |
| Other Comprehensive Income (11) | (23.25) | (99.72) | 4.60 | (79.49) | (11.67) | (52.39) | 1.90 | (46.65) |
| (12) Total Comprehensive Income (10+11) | 721.68 | 868.01 | 1,114.14 | 3,775.70 | 340.14 | 807.54 | 426.49 | 2,638.97 |



[Handwritten Signature]



| Particulars | Consolidated | | | | Standalone | | | |
|---|-----------------------|------------|------------|--------------------|-----------------------|------------|------------|--------------------|
| | For the Quarter ended | | | For the Year ended | For the Quarter ended | | | For the Year ended |
| | 30/06/2025 | 31/03/2025 | 30/06/2024 | 31/03/2025 | 30/06/2025 | 31/03/2025 | 30/06/2024 | 31/03/2025 |
| | Unaudited | Audited | Unaudited | Audited | Unaudited | Audited | Unaudited | Audited |
| Profit attributable to | | | | | | | | |
| - Owners of the Company | 744.93 | 967.73 | 1,109.54 | 3,855.19 | - | - | - | - |
| - Non - Controlling Interest | - | - | - | - | - | - | - | - |
| Other Comprehensive Income / (Loss) attributable to | | | | | | | | |
| - Owners of the Company | (23.25) | (99.72) | 4.60 | (79.49) | - | - | - | - |
| - Non - Controlling Interest | - | - | - | - | - | - | - | - |
| Total Comprehensive Income attributable to | | | | | | | | |
| - Owners of the Company | 2,907.69 | 868.01 | 1,114.14 | 3,775.70 | - | - | - | - |
| - Non - Controlling Interest | - | - | - | - | - | - | - | - |
| (13) Paid up Equity Share Capital (Face Value of Rs. 10 each) | 4,828.56 | 4,821.06 | 4,821.06 | 4,821.06 | 4,821.06 | 4,821.06 | 4,821.06 | 4,828.56 |
| (14) Other Equity | | | | 47,006.23 | | | | 38,315.22 |
| (15) Earnings Per Share (EPS) (Face value Rs. 10/- each) | | | | | | | | |
| (a) Basic | 1.54 | 2.01 | 2.30 | 7.99 | 0.73 | 1.78 | 0.88 | 5.57 |
| (b) Diluted | 1.54 | 2.01 | 2.30 | 7.99 | 0.73 | 1.78 | 0.87 | 5.57 |

Notes:-


- 1) The above Statement of consolidated and standalone unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act 2013, read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India. There is no minority interest.
- 2) The above Statement of consolidated and standalone unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on July 29, 2025 and have been reviewed by the Statutory Auditors of the Company who have expressed unmodified opinion.
- 3) The Company and the subsidiaries together referred to as "Group" are engaged primarily in the Pharmaceuticals business and there are no separate reportable segments as per Ind AS 108 on "Operating Segment Reporting".
- 4) Figures for the previous period have been regrouped or reclassified, wherever necessary to make them comparable with the figures of the current period.



Place : Mumbai
Date : July 29, 2025



FOR KOPRAN LIMITED


Surendra Somani
Executive Vice Chairman
DIN: 00600860

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of Kopran Limited pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Kopran Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Kopran Limited, ("the Company") for the quarter ended June 30, 2025 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



-2-

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KHANDELWAL JAIN & CO.
Chartered Accountants
Firm Registration No.: 105049W

Bhupendra Karkhanis

BHUPENDRA KARKHANIS
PARTNER

Membership No.: 108336
UDIN: 25108336BMJNQO8078



Place: Mumbai
Date: July 29, 2025.

6-B&C, Pil Court, 6th Floor,
111, M. Karve Road, Churchgate,
Mumbai - 400 020.
Tel.: (+91-22) 4311 5000
Fax : 4311 5050

12-B, Baldota Bhavan, 5th Floor,
117, M. Karve Road, Churchgate,
Mumbai - 400 020.
Tel.: (+91-22) 4311 6000
Fax : 4311 6060

Independent Auditor's Review Report on Quarterly Unaudited Consolidated Financial Results of Kopran Limited pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors of
Kopran Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Kopran Limited ("the Parent" or "the Holding Company") and its subsidiaries (the parent and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2025 ("the Statement"), attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard - 34 "Interim Financial Reporting" (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



-2-

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD 1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

List of Subsidiaries:

- Kopran Research Laboratories Limited
- Kopran Lifesciences Limited
- Kopran (H. K) Limited
- Kopran (UK) Limited (wholly owned subsidiary of Kopran Research Laboratories Limited)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. (a) We did not review the interim financial information of 2 subsidiaries included in the Unaudited Consolidated Financial Results, whose interim financial information, before consolidation adjustments, reflect total income of Rs. 8526.97 lakhs, total net profit after tax of Rs. 366.65 lakhs and total comprehensive income of Rs. 356.59 lakhs for the quarter ended June 30, 2025, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.
- Our conclusion on the Statement is not modified in respect of the above matter.



-3-

- (b) The Unaudited Consolidated Financial Results includes the interim financial information of 2 subsidiaries which have not been reviewed by their auditors, whose interim financial information, before consolidation adjustments, reflect total income of Rs. 31.42 lakhs, total net profit after tax of Rs. 1.09 lakhs and total comprehensive loss of Rs. 0.43 lakhs for the quarter ended June 30, 2025, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For KHANDELWAL JAIN & CO.

Chartered Accountants

Firm Registration No.: 105049W

Bhupendra



BHUPENDRA KARKHANIS
PARTNER

Membership No.: 108336

UDIN: 25108336BMJNQ6749

Place: Mumbai

Date: July 29, 2025.

SUSHEEL
SOMANI
404
OLYMPUS,
ALTAMOUNT
ROAD,
MUMBAI
400 026.

Date: July 10, 2025

To,
The Board of Directors
Kopran Limited
1076, Parijat House,
Dr. E Moses Road, Worli,
Mumbai - 400018.

Sub: Resignation as Non-Executive Director from the Board of Directors of Kopran Limited.

Dear All,


I, Susheel Gajadhar Somani (DIN: 00601727), hereby tender my resignation as a Non-Executive Director from the Board of Directors of Kopran Limited due to my continued ill health.

I kindly request the Board to consider and accept this letter of resignation. I further confirm that there are no material reasons for my resignation other than the one mentioned above.

I take this opportunity to express my gratitude to all the Members of the Board and the Management over the years for their valuable support that they have extended to me during my long tenure on the Board of this great Company.

I wish the organization continued success, growth and prosperity over the coming years.


Regards,



Susheel Gajadhar Somani
Director
DIN: 00601727

Place: Mumbai

For **Kopran Limited**



Company Secretary &
Compliance Officer



Received & Accepted
w.e.f. End of Business Hours
of July 29, 2025